clinical trial · NCT04155541
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Pfizer·—·completed·n = 40
EGFR Mutation-positive Inoperable or Reccrent NSCLCdacomitinib hydrate
brief summary
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
started
Jan 24, 2020
primary completion
Apr 25, 2025
completion
Apr 25, 2025
last updated
May 23, 2025
official title
Special Investigation for Vizimpro Tablets
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol